Get your free personalized podcast brief
We scan new podcasts and send you the top 5 insights daily.
The oncology landscape has evolved beyond a 'China vs. West' dynamic. Now, assets developed in China, such as Merck's partnered TROP2 ADC and Akiso's bispecific antibody, are positioned as direct competitors in the same indication, both backed by multinational pharma. This signifies the maturation of China's biotech innovation engine.
Related Insights
A notable trend is the licensing of advanced clinical assets from Chinese biotechs to major global pharmaceutical companies for ex-China rights. Deals like Roche licensing Medilink's Phase 3 ADC and AbbVie licensing Reamgen's Phase 2 bispecific antibody signal China's evolution from a market to a source of high-value, late-stage innovation.
AstraZeneca's two major partnerships with Chinese firms, Apple Zeta Pharma (CAR-T) and CSPC Pharmaceutical (obesity), signal a strategic pivot. The company is actively sourcing early-to-mid-stage assets from China for global development, treating the country as an innovation hub and validating the R&D capabilities of its biotech sector.
Western pharmaceutical companies are no longer seeking cheap 'me-too' assets in China. Instead, they are paying premium prices for genuinely innovative drugs, as evidenced by a 10x increase in deal size over five years and a surge in patent filings from the region.
Unlike past deals where Chinese firms kept only regional rights, new partnerships, like Hengri's with Bristol Myers, include options for co-commercialization globally. This signals a strategic shift from being regional R&D partners to becoming global commercial entities.
The panel reviews advanced, second-line ADC trials in China using novel targets and payloads. An expert remarks that these are the drugs and questions the US and Europe may only begin to study in two to three years, signaling a significant shift in the global oncology R&D landscape.
Beyond sheer scale, China's innovation leads in complex, next-generation drug modalities like ADCs and bispecifics. Chinese biotechs now account for roughly one-third of the global Phase 1 and 2 pipelines for these advanced therapies, indicating a shift from iteration on established targets to leadership in new technology platforms.
Driven by significant government investment, China is rapidly becoming a leader in biotech R&D, licensing, and outsourcing. This shift is a top-of-mind concern for US biotech and pharma executives, with China now involved in a majority of top R&D licensing deals.
The Sino Biopharmaceutical and Sanofi deal for rovodicitinib, a drug already approved in China, signals a key trend. Chinese biotechs are now developing and securing domestic approval for novel assets before out-licensing them for global commercialization, commanding significant upfront payments and billion-dollar milestone potentials.
In a major strategic shift, large pharmaceutical companies are increasingly sourcing their M&A pipeline from China. Chinese assets now account for 30-40% of Big Pharma's early-stage acquisitions, up from single digits just a few years ago, primarily because they are significantly cheaper than US or European equivalents.
The next decade in biotech will prioritize speed and cost, areas where Chinese companies excel. They rapidly and cheaply advance molecules to early clinical trials, attracting major pharma companies to acquire assets that they historically would have sourced from US biotechs. This is reshaping the global competitive landscape.
